PT
About
ProNAi Therapeutics is a clinical-stage oncology company that develops and commercializes drugs based on its DNA interference (DNAi) technology platform. Their lead candidate, PNT2258, targets the BCL2 gene to inhibit cancer cell proliferation and promote tumor cell death, and has been tested in Phase II clinical trials for various lymphomas.
Tags
Performance
Company Timeline
No timeline data for this period
Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does ProNAi Therapeutics do?
ProNAi Therapeutics is a clinical-stage oncology company that develops and commercializes drugs based on its DNA interference (DNAi) technology platform. Their lead candidate, PNT2258, targets the BCL2 gene to inhibit cancer cell proliferation and promote tumor cell death, and has been tested in Phase II clinical trials for various lymphomas.
How much funding has ProNAi Therapeutics raised?
ProNAi Therapeutics has raised a total of $76M in funding. The most recent round on record is Series D.
When was ProNAi Therapeutics founded?
ProNAi Therapeutics was founded in 2004.
What is ProNAi Therapeutics's current status?
ProNAi Therapeutics's current operating status is: Acquired.